PMV Pharmaceuticals (PMVP) Enterprise Value (2019 - 2026)
PMV Pharmaceuticals' (PMVP) quarterly Enterprise Value came in at -$93.5 million in Q1 2026, up 41.73% YoY from -$65.9 million in Q1 2025, and up 17.18% on a QoQ basis from -$112.8 million in Q4 2025.
PMV Pharmaceuticals (PMVP) Enterprise Value (2019 - 2026) Analysis & Trends
PMV Pharmaceuticals (PMVP) has 8 years of Enterprise Value data on file, last reported at -$93.5 million in Q1 2026.
- Quarterly Enterprise Value rose 41.73% year-over-year to -$93.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$93.5 million (up 41.73% YoY) and the FY2025 annual result came in at -$112.8 million, up 33.4% from the prior year.
- Enterprise Value rose to -$93.5 million in Q1 2026, from -$112.8 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$38.5 million in Q4 2023 to a low of -$229.4 million in Q1 2023.
- A 5-year average of -$126.9 million and a median of -$115.1 million in 2022 frame the typical range for Enterprise Value.
- The widest YoY moves for Enterprise Value: up 78.87% in 2024, down 339.82% in 2024.
- Tracing PMVP's Enterprise Value over 5 years: stood at -$109.1 million in 2022, then jumped by 64.69% to -$38.5 million in 2023, then slumped by 339.82% to -$169.5 million in 2024, then jumped by 33.4% to -$112.8 million in 2025, then gained by 17.18% to -$93.5 million in 2026.
- The last three Enterprise Value figures came in at -$93.5 million (Q1 2026), -$112.8 million (Q4 2025), and -$129.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 2.12 Bn |
| 10 | PMV Pharmaceuticals | 71.27 Mn | -8.16 Mn | - | -79.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -93.46 Mn |
| Dec 31, 2025 | -112.85 Mn |
| Sep 30, 2025 | -129.25 Mn |
| Jun 30, 2025 | -142.27 Mn |
| Mar 31, 2025 | -160.39 Mn |
| Dec 31, 2024 | -169.45 Mn |
| Sep 30, 2024 | -182.84 Mn |
| Jun 30, 2024 | -49.35 Mn |
| Mar 31, 2024 | -48.48 Mn |
| Dec 31, 2023 | -38.53 Mn |
| Sep 30, 2023 | -201.92 Mn |
| Jun 30, 2023 | -187.09 Mn |
| Mar 31, 2023 | -229.43 Mn |
| Dec 31, 2022 | -109.12 Mn |
| Sep 30, 2022 | -99.17 Mn |
| Jun 30, 2022 | -87.91 Mn |
| Mar 31, 2022 | -115.10 Mn |
| Dec 31, 2021 | -293.66 Mn |
| Sep 30, 2021 | -175.51 Mn |
| Jun 30, 2021 | -186.72 Mn |